Compare Abbott India with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs UNICHEM LAB - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA UNICHEM LAB ABBOTT INDIA/
UNICHEM LAB
 
P/E (TTM) x 47.0 61.3 76.6% View Chart
P/BV x 13.5 0.7 2,040.1% View Chart
Dividend Yield % 0.5 2.1 24.4%  

Financials

 ABBOTT INDIA   UNICHEM LAB
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
UNICHEM LAB
Mar-19
ABBOTT INDIA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs6,110292 2,092.5%   
Low Rs3,996182 2,195.6%   
Sales per share (Unadj.) Rs1,552.2167.7 925.8%  
Earnings per share (Unadj.) Rs188.8-3.6 -5,200.2%  
Cash flow per share (Unadj.) Rs196.45.9 3,305.9%  
Dividends per share (Unadj.) Rs55.004.00 1,375.0%  
Dividend yield (eoy) %1.11.7 64.5%  
Book value per share (Unadj.) Rs796.6372.3 214.0%  
Shares outstanding (eoy) m21.2570.38 30.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.31.4 230.3%   
Avg P/E ratio x26.8-65.3 -41.0%  
P/CF ratio (eoy) x25.739.9 64.5%  
Price / Book Value ratio x6.30.6 996.3%  
Dividend payout %29.1-110.2 -26.4%   
Avg Mkt Cap Rs m107,37616,680 643.7%   
No. of employees `0003.32.6 127.7%   
Total wages/salary Rs m3,9372,393 164.5%   
Avg. sales/employee Rs Th9,929.34,535.2 218.9%   
Avg. wages/employee Rs Th1,185.1919.8 128.8%   
Avg. net profit/employee Rs Th1,207.7-98.2 -1,229.8%   
INCOME DATA
Net Sales Rs m32,98511,801 279.5%  
Other income Rs m1,170984 118.9%   
Total revenues Rs m34,15512,785 267.2%   
Gross profit Rs m5,245-835 -628.2%  
Depreciation Rs m162674 24.0%   
Interest Rs m3875 50.8%   
Profit before tax Rs m6,215-600 -1,036.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,203-343 -641.3%   
Profit after tax Rs m4,012-256 -1,570.1%  
Gross profit margin %15.9-7.1 -224.7%  
Effective tax rate %35.457.3 61.9%   
Net profit margin %12.2-2.2 -561.7%  
BALANCE SHEET DATA
Current assets Rs m22,65520,384 111.1%   
Current liabilities Rs m6,6815,029 132.8%   
Net working cap to sales %48.4130.1 37.2%  
Current ratio x3.44.1 83.7%  
Inventory Days Days65105 61.8%  
Debtors Days Days29135 21.6%  
Net fixed assets Rs m8359,023 9.3%   
Share capital Rs m213141 150.9%   
"Free" reserves Rs m16,71526,058 64.1%   
Net worth Rs m16,92826,199 64.6%   
Long term debt Rs m00-   
Total assets Rs m24,16231,496 76.7%  
Interest coverage x163.7-7.0 -2,346.9%   
Debt to equity ratio x00-  
Sales to assets ratio x1.40.4 364.4%   
Return on assets %16.8-0.6 -2,927.8%  
Return on equity %23.7-1.0 -2,430.1%  
Return on capital %36.9-2.0 -1,847.6%  
Exports to sales %069.4 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3698,188 4.5%   
Fx outflow Rs m3,807596 638.7%   
Net fx Rs m-3,4387,592 -45.3%   
CASH FLOW
From Operations Rs m1,527-3,278 -46.6%  
From Investments Rs m-2,148-2,860 75.1%  
From Financial Activity Rs m-1,024-24 4,232.6%  
Net Cashflow Rs m-1,646-4,690 35.1%  

Share Holding

Indian Promoters % 0.0 50.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 15.1 52.3%  
FIIs % 0.1 3.0 3.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 31.7 53.9%  
Shareholders   18,270 20,176 90.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  ELDER PHARMA  NOVARTIS  PANACEA BIOTECH  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Oct 18, 2019 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS